GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice

Eur J Pharmacol. 2009 Jan 5;602(1):101-4. doi: 10.1016/j.ejphar.2008.10.065. Epub 2008 Nov 12.


In this study, we investigated the effects of GABA(A) and GABA(B) receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABA(B) receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABA(A) receptor agonist, had no significant effect. GABA(B) receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Baclofen / pharmacology*
  • Baclofen / therapeutic use
  • Cognition Disorders / chemically induced*
  • Cognition Disorders / drug therapy*
  • Dose-Response Relationship, Drug
  • GABA Agonists / pharmacology*
  • GABA Agonists / therapeutic use
  • Male
  • Memory / drug effects*
  • Methamphetamine* / adverse effects
  • Mice
  • Mice, Inbred ICR
  • Schizophrenia / drug therapy
  • Schizophrenia / physiopathology
  • Time Factors


  • GABA Agonists
  • Methamphetamine
  • Baclofen